Cargando…

Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome

We previously reported that a decrease in butyrate-producing bacteria in the gut is a potential cause of regulatory T cell (Treg) abnormalities in children with idiopathic nephrotic syndrome (INS). Therefore, we hypothesized that administration of butyrate-producing bacteria might reduce INS relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Tadashi, Tsuji, Shoji, Akagawa, Shohei, Akagawa, Yuko, Kino, Jiro, Yamanouchi, Sohsaku, Kimata, Takahisa, Hashiyada, Masaki, Akane, Atsushi, Kaneko, Kazunari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911438/
https://www.ncbi.nlm.nih.gov/pubmed/33530312
http://dx.doi.org/10.3390/nu13020365
_version_ 1783656341792882688
author Yamaguchi, Tadashi
Tsuji, Shoji
Akagawa, Shohei
Akagawa, Yuko
Kino, Jiro
Yamanouchi, Sohsaku
Kimata, Takahisa
Hashiyada, Masaki
Akane, Atsushi
Kaneko, Kazunari
author_facet Yamaguchi, Tadashi
Tsuji, Shoji
Akagawa, Shohei
Akagawa, Yuko
Kino, Jiro
Yamanouchi, Sohsaku
Kimata, Takahisa
Hashiyada, Masaki
Akane, Atsushi
Kaneko, Kazunari
author_sort Yamaguchi, Tadashi
collection PubMed
description We previously reported that a decrease in butyrate-producing bacteria in the gut is a potential cause of regulatory T cell (Treg) abnormalities in children with idiopathic nephrotic syndrome (INS). Therefore, we hypothesized that administration of butyrate-producing bacteria might reduce INS relapse and the need for immunosuppressants in these patients. Twenty patients in remission from INS (median age 5.3 years, 15 boys) were enrolled in the study and assigned to receive either daily oral treatment with a preparation of 3 g Clostridium butyricum or no probiotic treatment. The number of relapses and requirement for immunosuppressive agents were compared between the two groups. In the probiotic treatment group, analyses of the gut microbiota and Treg measurements were also performed. Probiotic-treated patients experienced fewer INS relapses per year compared with non-probiotic-treated patients (p = 0.016). Further, administration of rituximab in the probiotic treatment group was significantly less frequent compared with the non-probiotic-treated group (p = 0.025). In the probiotic treatment group, analyses before and after probiotic treatment revealed the significant increases in the relative abundance of butyrate-producing bacteria (p = 0.017) and blood Treg counts (p = 0.0065). Thus, oral administration of butyrate-producing bacteria during INS remission may reduce the frequency of relapse and the need for immunosuppressive agents.
format Online
Article
Text
id pubmed-7911438
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79114382021-02-28 Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome Yamaguchi, Tadashi Tsuji, Shoji Akagawa, Shohei Akagawa, Yuko Kino, Jiro Yamanouchi, Sohsaku Kimata, Takahisa Hashiyada, Masaki Akane, Atsushi Kaneko, Kazunari Nutrients Article We previously reported that a decrease in butyrate-producing bacteria in the gut is a potential cause of regulatory T cell (Treg) abnormalities in children with idiopathic nephrotic syndrome (INS). Therefore, we hypothesized that administration of butyrate-producing bacteria might reduce INS relapse and the need for immunosuppressants in these patients. Twenty patients in remission from INS (median age 5.3 years, 15 boys) were enrolled in the study and assigned to receive either daily oral treatment with a preparation of 3 g Clostridium butyricum or no probiotic treatment. The number of relapses and requirement for immunosuppressive agents were compared between the two groups. In the probiotic treatment group, analyses of the gut microbiota and Treg measurements were also performed. Probiotic-treated patients experienced fewer INS relapses per year compared with non-probiotic-treated patients (p = 0.016). Further, administration of rituximab in the probiotic treatment group was significantly less frequent compared with the non-probiotic-treated group (p = 0.025). In the probiotic treatment group, analyses before and after probiotic treatment revealed the significant increases in the relative abundance of butyrate-producing bacteria (p = 0.017) and blood Treg counts (p = 0.0065). Thus, oral administration of butyrate-producing bacteria during INS remission may reduce the frequency of relapse and the need for immunosuppressive agents. MDPI 2021-01-26 /pmc/articles/PMC7911438/ /pubmed/33530312 http://dx.doi.org/10.3390/nu13020365 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamaguchi, Tadashi
Tsuji, Shoji
Akagawa, Shohei
Akagawa, Yuko
Kino, Jiro
Yamanouchi, Sohsaku
Kimata, Takahisa
Hashiyada, Masaki
Akane, Atsushi
Kaneko, Kazunari
Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome
title Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome
title_full Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome
title_fullStr Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome
title_full_unstemmed Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome
title_short Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome
title_sort clinical significance of probiotics for children with idiopathic nephrotic syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911438/
https://www.ncbi.nlm.nih.gov/pubmed/33530312
http://dx.doi.org/10.3390/nu13020365
work_keys_str_mv AT yamaguchitadashi clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome
AT tsujishoji clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome
AT akagawashohei clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome
AT akagawayuko clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome
AT kinojiro clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome
AT yamanouchisohsaku clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome
AT kimatatakahisa clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome
AT hashiyadamasaki clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome
AT akaneatsushi clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome
AT kanekokazunari clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome